Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma
NCT06151236
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Merkel Cell Carcinoma
Interventions
DRUG:
Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination
Sponsor
Melanoma Institute Australia
Collaborators
[object Object]